Market Overview

BrainScope Receives Prix Galien Award Nomination for Its Concussion and Traumatic Brain Injury Assessment Product


BrainScope today announced its second consecutive nomination for the
2018 Annual Prix Galien USA Awards for "Best Medical Technology"
product. Its flagship BrainScope One product is a multi-modal,
comprehensive, handheld capability to help clinicians objectively and
rapidly assess and triage head injured patients directly at the point of

This press release features multimedia. View the full release here:

FDA-Cleared BrainScope One (Photo: Business Wire)

FDA-Cleared BrainScope One (Photo: Business Wire)

BrainScope's innovative technology addresses a vast market need for the
global epidemic of mild head injury, which impacts more people each year
than stroke and heart failure combined. BrainScope One is the
first FDA-cleared medical device to offer capabilities to assess the
full spectrum of brain injury – from concussions (functional
abnormality) to brain bleeds (structural injury). Recent white papers
authored by third parties have shown the potential for BrainScope One
to decrease unnecessary head CT scans by one-third, to reduce head
injury referrals to emergency departments by up to 75% and to reduce
healthcare costs for payers and patients by over 30%.

The Prix Galien USA Awards are bestowed by the Galien Foundation which
"…fosters, recognizes and rewards excellence in scientific innovation to
improve the state of human health. It is widely regarded as the
equivalent of the Nobel Prize in biopharmaceutical and medical
technology research." Nominees are evaluated by a committee of twelve
esteemed scientific leaders from the biopharmaceutical industry and
academia, including four Noble Laureates. As one of ten nominees for
"Best Medical Technology", BrainScope stands among prominent medical
device companies such as Abbott, Boston Scientific and Medtronic.

BrainScope CEO Michael Singer stated, "It is a tremendous honor to be
nominated for the Prix Galien USA award, and to be nominated twice is a
testament to our team's efforts in creating tangible scientific and
health impacts with the creation and commercialization of BrainScope
. We are grateful to the Galien Foundation for its recognition of
our innovation and dedication to providing the public with objective and
comprehensive neurological assessment capabilities addressing the global
brain injury problem."

About BrainScope

BrainScope's mission is to revolutionize the rapid and objective
assessment of brain-related conditions, starting with concussion and
mild traumatic brain injury, utilizing multiple integrated assessment
capabilities, artificial intelligence (AI) and digitization within a
culture of quality, excellence and entrepreneurialism. The Company's
first product introduced in 2017, BrainScope One (cleared as Ahead
, incorporates a multi-modal panel of capabilities including
EEG-based technology that is non-invasive for mildly presenting head
injured patients, 18-85 years old, within 3 days after injury and is not
a replacement to CT scan. BrainScope's technology platform integrates
databases of thousands of brainwave recordings with AI technology and
miniaturized hardware and disposable headset sensors, all of which are
covered by an extensive intellectual property portfolio of over 100
issued and pending patents globally. BrainScope has received five FDA
clearances and ISO 13485:2003 Certification. It has 24 peer-reviewed
publications on its technology. BrainScope has partnered with the U.S.
Department of Defense for the development of its TBI assessment
technology, and BrainScope One is currently being fielded by the
U.S. military, both stateside and internationally. BrainScope One
is also being utilized in a cross-section of market segments including:
urgent care and occupational health clinics; concussion clinics;
hospital emergency rooms; university sports and student health centers;
professional sports; and pharmaceutical clinical trials. BrainScope has
been the recipient of several prestigious awards, including the Frost &
Sullivan 2017 Best Practices Award for New Product Innovation in the
Traumatic Brain Injury Assessment Solutions Market, was a two-time
winner of the GE-NFL Head Health Challenge, and has now received two
nominations for the Prix Galien Best Medical Technology, regarded as the
equivalent of the Nobel Prize for medical devices. For more information,
please visit

View Comments and Join the Discussion!